scispace - formally typeset
Open AccessJournal Article

Clinical course and outcome of rheumatoid arthritis-related usual interstitial pneumonia.

Reads0
Chats0
TLDR
Overall prognosis of RA-UIP was significantly better than that of IPF matched with age, sex, smoking and baseline lung function and the treatment of the patients with significant functional impairments or progression was supported.
Citations
More filters
Journal ArticleDOI

Predictors of mortality in rheumatoid arthritis-associated interstitial lung disease

TL;DR: Data from this study suggest that in rheumatoid-arthritis associated interstitial lung disease, disease progression and survival differ between subgroups defined by HRCT pattern; however, when controlling for potentially influential variables, pulmonary physiology, but notHRCT pattern, independently predicts mortality.
Journal ArticleDOI

A population-based cohort study of rheumatoid arthritis-associated interstitial lung disease: comorbidity and mortality

TL;DR: ILD is a serious complication in RA, with a significantly increased mortality compared with a large matched cohort of RA comparisons without ILD, and the HRR for death was highest in the first months after the diagnosis of RA-ILD was made.
Journal ArticleDOI

What's in a name? That which we call IPF, by any other name would act the same.

TL;DR: The clinical and pathogenetic justification for a focus on “the progressive fibrotic phenotype” in future clinical and translational research is summarised, to address the needs of non-IPF patients with inexorably progressive Fibrotic disease, currently disenfranchised by lack of access to agents that are efficacious in IPF.
Journal ArticleDOI

The Lung in Rheumatoid Arthritis: Focus on Interstitial Lung Disease.

TL;DR: Concerted multinational efforts by expert centers has the potential to elucidate the basic mechanisms underlying RA‐related UIP and other subtypes of RA‐ related ILD and facilitate the development of more efficacious and safer drugs.
Journal ArticleDOI

Fibrosing interstitial lung diseases: knowns and unknowns.

TL;DR: It is postulated that, once the response to lung injury in fibrosing ILDs has reached the stage at which fibrosis has become progressive and self-sustaining, targeted antifibrotic therapy would be required to slow disease progression.
Related Papers (5)